209 related articles for article (PubMed ID: 7570044)
1. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).
Olsen JO; Pozderac RV; Hinkle G; Hill T; O'Dorisio TM; Schirmer WJ; Ellison EC; O'Dorisio MS
Semin Nucl Med; 1995 Jul; 25(3):251-61. PubMed ID: 7570044
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor imaging.
Kwekkeboom DJ; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):84-91. PubMed ID: 11965603
[TBL] [Abstract][Full Text] [Related]
3. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
4. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors.
Modlin IM; Cornelius E; Lawton GP
Arch Surg; 1995 Apr; 130(4):367-73; discussion 373-4. PubMed ID: 7710334
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin-receptor imaging in lymphoma.
Goldsmith SJ; Macapinlac HA; O'Brien JP
Semin Nucl Med; 1995 Jul; 25(3):262-71. PubMed ID: 7570045
[TBL] [Abstract][Full Text] [Related]
7. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
Otte A; Jermann E; Behe M; Goetze M; Bucher HC; Roser HW; Heppeler A; Mueller-Brand J; Maecke HR
Eur J Nucl Med; 1997 Jul; 24(7):792-5. PubMed ID: 9211767
[TBL] [Abstract][Full Text] [Related]
8. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
[No Abstract] [Full Text] [Related]
9. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results.
Krenning EP; Kwekkeboom DJ; Oei HY; de Jong RJ; Dop FJ; Reubi JC; Lamberts SW
Ann N Y Acad Sci; 1994 Sep; 733():416-24. PubMed ID: 7978890
[No Abstract] [Full Text] [Related]
10. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview.
Warner RR; O'dorisio TM
Semin Nucl Med; 2002 Apr; 32(2):79-83. PubMed ID: 11965602
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary results on the use of scintigraphy with radiolabelled octreotide as diagnostic method in neuroendocrine and nonendocrine neoplasms of the lung].
Oliaro A; Filosso PL; Bellò M; Casadio C; Muni A; Angusti T; Masaneo I; Bisi G; Maggi G
Minerva Chir; 1997 Nov; 52(11):1335-8. PubMed ID: 9489331
[TBL] [Abstract][Full Text] [Related]
12. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
Banzo J; Abós MD; Prats E; García F; Razola P
Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
[No Abstract] [Full Text] [Related]
13. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
Pauwels S; Leners N; Fiasse R; Jamar F
Semin Oncol; 1994 Oct; 21(5 Suppl 13):15-20. PubMed ID: 7992075
[No Abstract] [Full Text] [Related]
14. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
[TBL] [Abstract][Full Text] [Related]
15. [Imaging of pediatric brain tumors using somatostatin analogue 111Ih-DTPA-D-Phe1-octreotide].
Dabasi G; Hauser P; Kertész GP; Balázs G; Karádi Z; Constantin T; Bognár L; Klekner A; Schuler D; Garami M
Magy Onkol; 2007; 51(3):229-34. PubMed ID: 17922063
[TBL] [Abstract][Full Text] [Related]
16. [The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
Chiti A; Spinelli A; Bombardieri E
Radiol Med; 1997 Oct; 94(4):362-70. PubMed ID: 9465244
[No Abstract] [Full Text] [Related]
17. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
[TBL] [Abstract][Full Text] [Related]
18. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
[TBL] [Abstract][Full Text] [Related]
19. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.
Balon HR; Goldsmith SJ; Siegel BA; Silberstein EB; Krenning EP; Lang O; Donohoe KJ;
J Nucl Med; 2001 Jul; 42(7):1134-8. PubMed ID: 11438641
[No Abstract] [Full Text] [Related]
20. Peptide receptor imaging and therapy.
Kwekkeboom D; Krenning EP; de Jong M
J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
